Archives
-
Nifedipine (BAY-a-1040) for Cell Assays
2026-09-25
A scenario-driven guide to using Nifedipine (BAY-a-1040), SKU B1988, in calcium-dependent cell assays. It covers dose planning, vehicle controls, interpretation across research models, and practical product-selection considerations without overstating the evidence.
-
Y-27632 Dihydrochloride: ROCK Inhibition in Practice
2026-09-24
Use Y-27632 dihydrochloride to probe ROCK-dependent cytoskeletal organization, cell survival, and invasion with workflows built around dose-response testing and exposure-history controls. This guide separates product characteristics from proposed pilot conditions and highlights how to avoid mistaking altered cell number or viability for a pathway-specific effect.
-
Clarithromycin CYP3A Inhibitor Assay Workflows
2026-09-24
Use Clarithromycin to probe CYP3A-mediated metabolism in controlled microsomal workflows, including statin metabolism interaction experiments. This guide pairs practical assay setup and troubleshooting with an important boundary: in vitro inhibition helps define interaction potential, but does not by itself predict a clinical outcome.
-
circHIF1A Links LUAD Growth to M2 Polarization
2026-09-23
A study of lung adenocarcinoma (LUAD) identifies a circHIF1A/miR-486-5p/GRHL2 regulatory axis associated with tumor-cell aggressiveness and macrophage M2 polarization. Its findings connect a circular RNA ceRNA mechanism to immune-microenvironment changes, while highlighting the need for further validation of the axis in clinically representative models.
-
GS967: A Causal Assay Framework for Late INa
2026-09-23
GS967 is a cardiac late sodium current inhibitor for connecting Nav1.5 dysfunction with repolarization, calcium handling, and arrhythmia phenotypes. This article presents a causal assay framework that combines acute pharmacology, engineered sodium-channel models, and tissue-level electrophysiology.
-
IDH2, Ferroptosis, and TNBC Proliferation
2026-09-22
The reference study identifies IDH2 as a redox-linked regulator of triple-negative breast cancer proliferation and connects its activity to suppression of ferroptosis. By combining tumor-data analysis with clinical, cellular, and mouse-model validation, the work provides a mechanistic framework for studying how metabolic state influences TNBC growth.
-
X-press Tag Peptide for RHEB Assays
2026-09-22
X-press Tag Peptide combines polyhistidine capture, Xpress epitope readout, and an enterokinase-compatible cleavage site in one N-terminal leader peptide. This article translates that three-part design into practical ProBond purification, Anti-Xpress antibody detection, and RHEB neddylation assay workflows while separating product specifications from optimization starting points.
-
(+)-Bicuculline: Practical GABAA Workflow
2026-09-21
(+)-Bicuculline is a competitive GABAA receptor antagonist used to reduce GABAergic inhibition in controlled neuroscience assays. This guide addresses dissolution, storage, experimental controls, and interpretation; the compound is for research use only and should not be used for diagnostic, clinical, or therapeutic purposes.
-
Carbapenemase Gene Spread in CREC, 2022–2024
2026-09-21
A 2025 BMC Microbiology study combined gene localization, antimicrobial susceptibility testing, conjugation experiments, mobile-element analysis, and strain typing to examine carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. Its findings emphasize plasmid-associated blaNDM-1, extensive multidrug resistance, and efficient horizontal transmission, while also identifying the limits of hospital-based cross-sectional surveillance.
-
7-Ethyl-10-hydroxycamptothecin Workflow Guide
2026-09-20
Build reproducible SN-38 assays around topoisomerase I inhibition, apoptosis, and S-phase/G2-phase profiling. This practical guide also shows how to extend colon cancer experiments with the FUBP1/FUSE mechanism reported in the reference study.
-
Hexamethonium Bromide for Reliable Assays
2026-09-19
Hexamethonium Bromide (SKU B1592) offers a defined pharmacological control for studying neuronal nicotinic acetylcholine receptor signaling alongside cell viability, proliferation, and cytotoxicity assays. This scenario-based guide connects product specifications, autonomic research evidence, solution handling, and data interpretation to more reproducible laboratory workflows.
-
Fosinopril Sodium: A Translational ACE Inhibitor Roadmap
2026-09-18
Fosinopril sodium offers translational researchers a mechanistically defined way to connect ACE inhibition with blood pressure regulation, renal hemodynamics modulation, and cardiovascular remodeling. This thought-leadership guide combines molecular rationale, model-design recommendations, formulation controls, competitive positioning, and evidence-aware strategies for hypertension research and cardiovascular disease models.
-
Mitoxantrone HCl in DNA Damage Workflows
2026-09-18
Mitoxantrone HCl combines a well-established DNA topoisomerase II inhibitor profile with an emerging ERα allosteric mechanism that can be tested in resistance-focused assays. This guide translates those findings into practical stock preparation, cell-based screening, mechanism validation, and troubleshooting workflows.
-
Candida krusei Apoptosis in Bovine Mammary Cells
2026-09-17
Miao et al. show that the yeast and hypha phases of Candida krusei induce bovine mammary epithelial cell apoptosis through different mechanisms. The study links the yeast form primarily to mitochondrial dysfunction and the hypha form to death ligand/receptor signaling, while implicating TLR2/ERK and JNK/ERK pathways in both responses.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-09-17
Breen et al. developed a genetically drug-sensitized Saccharomyces cerevisiae platform that markedly improves detection of TOR/mTOR inhibitors compared with wild-type yeast. The study provides a rapid screening framework, while its negative result for nebivolol illustrates why assay-specific evidence should not be generalized across mammalian signaling systems.